Phase II Study of Sequential Methotrexate and 5-Fluorouracil Chemotherapy Against Peritoneally Disseminated Gastric Cancer with Malignant Ascites: a Report from the Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group, JCOG 9603 Trial
Authors:
- Yasuhiro ShimadaYSYasuhiro Shimada
- Kuniaki ShiraoKSKuniaki Shirao
- Atsushi OhtsuAOAtsushi Ohtsu
- Nobumasa IkedaNINobumasa Ikeda
- Ichinosuke HyodoIHIchinosuke Hyodo
- Hiroshi SaitoHSHiroshi Saito
- Hiroaki IwaseHIHiroaki Iwase
- Yasushi TsujiYTYasushi Tsuji
- Takao TamuraTTTakao Tamura
- Seiichiro YamamotoSYSeiichiro Yamamoto
- Shigeaki YoshidaSYShigeaki Yoshida
Open Access
- 1 June 2004
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 34 (6) , 316-322
Abstract
Background: The efficacy of systemic chemotherapy against peritoneal dissemination from advanced gastric cancer (AGC) remains unclear, because the peritoneal dissemination was not defined as a measurable lesion in conventional phase II studies. In this study, we evaluated the efficacy and toxicity of sequential MTX and 5FU therapy (MF) in chemotherapy-naive patients with AGC accompanied by malignant ascites in a phase II setting. Methods: The treatment schedule comprised weekly administration of MTX (100 mg/m2, i.v. bolus) followed by 5FU (600 mg/m2, i.v. bolus) with a 3 h interval. Leucovorin rescue (10 mg/m2 every 6 h, for a total of six times) was commenced 24 h after MTX administration. Results: Thirty-seven chemotherapy-naive patients with AGC presenting with malignant ascites were enrolled in this trial. The median age was 60 years (range, 25–74 years) and most patients (86%) had a performance status of 0–1. In total, 355 administrations of the sequential MTX/5FU therapy were performed. Major toxicity consisted of myelosuppression and gastrointestinal toxicity. Grade 4 neutropenia occurred in 10.8% of the patients. The overall objective response rate was 5.7% (two partial responses in 35 patients; 95% confidence interval: 0.7–19.2%). However, the response rate of ascites was 35.1% (complete disappearance in three patients and apparent decrease in 10 patients; 95% confidence interval: 20.2–52.5%). Conclusions: Sequential MTX/5FU therapy is effective against AGC with malignant ascites with acceptable toxicity and warrants further investigations in a phase III setting.Keywords
This publication has 16 references indexed in Scilit:
- Randomized Phase III Trial of Fluorouracil Alone Versus Fluorouracil Plus Cisplatin Versus Uracil and Tegafur Plus Mitomycin in Patients With Unresectable, Advanced Gastric Cancer: The Japan Clinical Oncology Group Study (JCOG9205)Journal of Clinical Oncology, 2003
- Biochemical Modulation of 5-Fluorouracil by Methotrexate in Patients With Advanced Gastric CarcinomaAmerican Journal of Clinical Oncology, 1998
- Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancerBritish Journal of Cancer, 1995
- Initial or delayed chemotherapy with best supportive care in advanced gastric cancerAnnals of Oncology, 1994
- Toxicity Grading Criteria of the Japan Clinical Oncology GroupJapanese Journal of Clinical Oncology, 1993
- Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancerCancer, 1993
- Activities of thymidylate synthetase and thymidine kinase in gastric cancerSurgical Oncology, 1992
- 5-fluorouracil-methotrexate synergy: enhancement of 5-fluorodeoxyridylate binding to thymidylate synthase by dihydropteroylpolyglutamates.Proceedings of the National Academy of Sciences, 1980
- Enhanced 5-Fluorouracil Nucleotide Formation After Methotrexate Administration: Explanation for Drug SynergismScience, 1979
- Methotrexate Disposition in Humans: Case Studies in Ovarian Cancer and Following High-Dose InfusionDrug Metabolism Reviews, 1978